Poly(ADP-Ribose) Polymerase Inhibitors

Poly(ADP-Ribose) Polymerase Inhibitor

Ovarian Neoplasms

<section class="Section" data-sectioncode="34089-3"><a name="s39"></a><a name="section-9"></a><p></p><h1>11 DESCRIPTION</h1><p class="First">Rucaparib is an inhibitor of the mammalian polyadenosine 5'-diphosphoribose polymerase (PARP) enzyme. The chemical name is 8-fluoro-2-{4-[(methylamino)methyl]phenyl}-1,3,4,5-tetrahydro-6H-azepino[5,4,3-cd]indol-6-one ((1S,4R)-7,7-dimethyl-2-oxobicyclo[2.2.1]hept-1-yl)methanesulfonic acid salt. The chemical formula of rucaparib camsylate is C   <span class="Sub">19</span>H   <span class="Sub">18</span>FN   <span class="Sub">3</span>O•C   <span class="Sub">10</span>H   <span class="Sub">16</span>O   <span class="Sub">4</span>S and the relative molecular mass is 555.67 Daltons. </p><p>The chemical structure of rucaparib camsylate is shown below:</p><div class="Figure"><a name="f01"></a><img alt="structural formula " src="rub01-0018-01.jpg"/></div><p>Rucaparib camsylate is a white to pale yellow powder; formulated into a tablet for oral use. Rucaparib shows pH-independent low solubility of approximately 1 mg/mL across the physiological pH range.</p><p>Rubraca (rucaparib) tablets contain rucaparib camsylate as the active ingredient. Each 200 mg tablet contains 344 mg rucaparib camsylate equivalent to 200 mg rucaparib free base. Each 250 mg tablet contains 430 mg rucaparib camsylate equivalent to 250 mg rucaparib free base. Each 300 mg tablet contains 516 mg rucaparib camsylate equivalent to 300 mg rucaparib free base.</p><p>The inactive ingredients in Rubraca tablets include: microcrystalline cellulose, sodium starch glycolate, colloidal silicon dioxide, and magnesium stearate. The cosmetic blue film coating for 200 mg tablets, cosmetic white film coating for 250 mg tablets, and cosmetic yellow film coating for 300 mg tablets is Opadry II containing polyvinyl alcohol, titanium dioxide, polyethylene glycol/macrogol, and talc. The coating is colorized as blue using brilliant blue aluminum lake and indigo carmine aluminum lake, or yellow using yellow iron oxide.</p></section>

Rubraca

rucaparib

rucaparib 300 MG Oral Tablet

rucaparib 300 MG Oral Tablet [Rubraca]

rucaparib 200 MG Oral Tablet

rucaparib 200 MG Oral Tablet [Rubraca]

rucaparib 250 MG Oral Tablet

rucaparib 250 MG Oral Tablet [Rubraca]

Psoriasis (PsO)

Psoriatic Arthritis (PsA)

Ankylosing Spondylitis (AS)

Nonradiographic Axial Spondyloarthritis

Taltz

Juvenile Idiopathic Arthritis

Hidradenitis Suppurativa (HS)

Cosentyx

Siliq

Tremfya

Crohn's Disease (CD)

Ulcerative Colitis (UC)

Stelara

Skyrizi

Ilumya

Migraine

Cluster Headache

Migraine Prevention

Emgality

Qulipta

Acute Migraine

Ubrelvy

Nurtec ODT

Vyepti

Aimovig

Ajovy

Breast Cancer: HR+ (HER2-)

Verzenio

Ibrance

Kisqali

Atopic Dermatitis (Eczema)

Cibinqo

Eucrisa

Asthma (injectable)

Asthma OCS Dependent

Nasal Polyposis

Eosinophilic Esophagitis (EoE)

Prurigo Nodularis

Dupixent

Opzelura

Adbry

NSCLC ALK+ OR ROS1+ Disease

Lorbrena

Alecensa

Alunbrig

NSCLC cMET Mutation

Xalkori

Rheumatoid Arthritis (RA)

Xeljanz

Uveitis

Graft Versus Host Disease (GVHD)

Orencia

COVID-19 Treatment

Alopecia Areata

Olumiant

Multiple Sclerosis (MS)

Secondary Progressive Multiple Sclerosis

Zeposia

Rinvoq

Entyvio

Report Adverse Event 

Prescribing Information

Medication Guide 

Pharmacy List 

Submit MSL Request 

Coverage Authorization Request 

Coverage Authorization Appeals 

Letter of Medical Necessity 

Rubraca Enrollment and Comprehensive Support Form

Rubraca Enrollment and Comprehensive Support Form - Online

Instructions For Use: 2L+ Maintenance Recurrent Ovarian Cancer 

Instructions For Use: BRCAmut+ Metastatic Castration-Resistant Prostate Cancer 

Patient Brochure: BRCAmut+ Metastatic Castration-Resistant Prostate Cancer 

Doctor Discussion Guide: BRCAmut+ Metastatic Castration-Resistant Prostate Cancer 

Side Effect Guide: BRCAmut+ Metastatic Castration-Resistant Prostate Cancer 

Rubraca Enrollment & Comprehensive Support Form 